introduction Anemia is common in cancer patients, and its etiology is multifactorial, including blood loss, bone marrow invasion, the anemia of chronic disease, and treatment-induced inhibition of erythropoiesis. Anemia, whether present at baseline before the initiation of therapy or arising during treatment, has been associated with a poorer outcome from radiation or chemoradiation for cancers of the head and neck [1] , cervix [2] , and non-small-cell lung cancer (NSCLC) [3] . It is not known whether this association is causative (anemia leading to relative tumor hypoxia and thus to radioresistance) or simply prognostic or predictive.
Small-cell lung cancer (SCLC) accounts for 15% of all lung malignancies. For patients with limited-stage disease, standard therapy consists of cisplatin-etoposide (EP) combination chemotherapy [4] given with early, concurrent thoracic radiotherapy [5, 6] . In patients who are able to tolerate such combined modality therapy, 5-year survival rates of up to 26% have been reported [7] . There are several accepted prognostic factors for outcome of therapy with chemoradiation in limited small-cell lung cancer (LD-SCLC), including gender, performance status (PS), and serum lactate dehydrogenase (LDH) levels [8] [9] [10] . There are limited and conflicting data on the impact of baseline anemia on LD-SCLC, with some reporting a negative impact [9] while others report no association [11, 12] .
To examine the potential association between anemia and outcome in LD-SCLC, we undertook this retrospective analysis of data from two previously reported multicenter randomized controlled trials conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) [5, 13] . Compared with institutional retrospective reviews, this analysis has the benefit of a large number of homogenously treated patients with a low rate of missing data.
patients and methods patients
The NCIC CTG has conducted two randomized controlled trials in LD-SCLC, BR.3, and BR. 6 [5, 13] . BR.3 randomized patients to receive six cycles of chemotherapy with EP and cyclophosphamide-doxorubicin-vincristine (CAV) given in either a sequential (three cycles of CAV followed by three cycles of EP) or alternating fashion. In this trial, thoracic radiotherapy (either 37.5 Gy in 15 fractions or 25 Gy in 10 fractions, at the institution's discretion) was administered to all patients following the completion of chemotherapy, while prophylactic cranial irradiation (PCI) (20 Gy in five fractions) was administered to all patients during week 7. BR.6 was designed to evaluate the importance of early versus late concurrent thoracic radiotherapy. All patients received six cycles of alternating CAV/EP, with thoracic radiotherapy (40 Gy in 15 fractions) administered concurrently with either cycle 2 or 6 of chemotherapy. PCI (25 Gy in 10 fractions) was administered following the completion of chemoradiation. Three hundred and twenty-two patients were enrolled to BR.3 and 330 to BR.6. Thus, a total of 652 patients are the subject of this report.
statistical methods
Exploratory analyses were carried out to characterize the relationships between various hemoglobin (Hb) parameters and patient characteristics and treatment outcomes. The Hb parameters examined were those that had been found to be associated with outcome in other malignancies [1-3, 14, 15] and included baseline Hb (before initiation of any therapy) dichotomized as normal versus low (<136 g/l for men, <120 g/l for women); nadir Hb during treatment (<100 g/l versus ‡100 g/l); maximum percentage drop from baseline (<10% versus 10%-30% versus >30%); and Hb level immediately before the initiation of PCI (pre-PCI Hb) (<100 g/l versus ‡100 g/l).
Overall and progression-free survivals were defined as the time from randomization until death from any cause or until disease progression or death, respectively. Local disease control was defined as the time from randomization to the time of disease progression in the chest (or in the central nervous system (CNS), for analyses related to PCI). Kaplan-Meier curves were used to estimate the distributions of the time-to-event outcomes [16] . The log-rank test [17] was used to assess the association between Hb level and these time-to-event outcomes. A chi-square test or Fisher's exact test [18] was used to assess associations between categorical variables, while the Cox regression model [19] , stratified by treatment arm, using a stepwise procedure with a significance level of 0.1 for factors to stay, was used to study the effect of Hb level on time-to-event outcomes while adjusting for baseline prognostic factors. These factors included gender, age, Eastern Cooperative Oncology Group (ECOG) PS, body surface area (BSA), race, and LDH. The data were analyzed using the statistical package SASÒ Version 8.2 (SAS Institute Inc., Cary, NC). All reported P values are from two-sided tests unless otherwise specified.
results baseline Hb
Of the 652 patients randomized in BR.3 and BR.6, a low baseline Hb was present in 32% (210) of patients (Table 1) . Males (P < 0.001), patients >65 (P = 0.03), those with ECOG PS ‡2 (P = 0.02), and those with increased LDH (P = 0.03) were more likely to present with low baseline Hb. Race, BSA, trial or treatment arm were not associated with baseline Hb value. Tables 2, 3 and 4 summarize the impact of the various Hb parameters on outcomes, as well as those baseline prognostic factors that did have an independent association with outcome. Baseline Hb was not statistically associated with either overall (P = 0.58) or progression-free survival (P = 0.35) in univariate analysis (log-rank test stratified by treatment). In the multivariate Cox regression model stratified by treatment arm, male gender, a PS ‡2, and an elevated LDH were associated with poorer overall and progression-free survival, while baseline Hb remained nonsignificant. Similarly, baseline Hb had no impact on the rate of local (chest) progression/relapse (P = 0.62) ( Table 2) .
nadir Hb during therapy and maximum percentage drop
Of the 652 patients in BR.3 and BR.6, 633 had at least one Hb value recorded during treatment and were included in the analysis. Nadir Hb during treatment of ‡grade 2 (<100 g/l) was observed in 55% of patients. Baseline factors that were associated with ‡grade 2 nadir Hb during treatment included female gender (P < 0.001), presence of a baseline low Hb (P < 0.001), age >65 (P = 0.002), and a BSA of <2 (P < 0.001). Univariate analysis (log-rank test stratified by treatment arm and baseline Hb level) showed that nadir Hb was not independently associated with overall (P = 0.79) or progression-free survival (P = 0.2). Those with a nadir Hb <100 g/l, however, had a longer duration of freedom from local (chest) recurrence [Hazard ratio (HR) = 0.70, 95% confidence interval (CI) 0.54-0.90, P = 0.005; Figure 1 ]. Multivariate Cox regression analysis showed that males had a higher risk of local progression (HR = 1.6, 95% CI 1.2-2.1; P = 0.001), while a nadir Hb <100 g/l remained marginally significant (P = 0.06) ( Table 3 ). Similar analyses showed that the maximum percentage drop in Hb from baseline did not predict for survival (P = 0.27), nor did it predict local progression (P = 0.33) ( Table 4) .
immediate pre-PCI Hb
This analysis was restricted to the 523 patients who received PCI. A lower Hb immediately before the initiation of PCI was associated with pretreatment anemia (P < 0.001), age >65 (P = 0.004), female gender (P < 0.001), ECOG PS ‡2 (P = 0.04), BSA <2 (P < 0.001), and enrollment to trial BR.6 (P < 0.001).
A low pre-PCI Hb, however, was not associated with an increased risk of local (CNS) relapse (P = 0.31).
effect of dose intensity of chemotherapy and dose of radiation on outcomes Multivariate Cox regression analyses stratified by treatment arm and baseline Hb level were also carried out to evaluate the effect of minimum Hb level on outcomes, while adjusting for chemotherapy and radiotherapy dose/dose intensity, as well as baseline age, gender, ECOG PS, BSA, race, and LDH. These analyses revealed that there was no impact of either chemotherapy or radiotherapy doses or dose intensity on outcomes.
discussion
The current analysis of two randomized trials carried out by the NCIC CTG enrolling >600 patients with LD-SCLC was designed to investigate the impact of anemia, both at baseline and arising during treatment, on outcomes. It confirmed, as have other studies, that male gender, poor PS, and an elevated LDH are negative prognostic factors in this disease. The impact of anemia, however, is less clear. Consistent with what others have observed [11, 20] , anemia is common at diagnosis in patients with LD-SCLC, seen in one-third of patients enrolled to these two trials. The data on whether baseline pretreatment anemia is a negative prognostic factor in LD-SCLC are conflicting, with reports both supporting [9] and, as in the current study, not observing [10] [11] [12] an association. Any association between baseline anemia and poorer outcome is not necessarily causative, as it may be that anemia at presentation is simply another surrogate marker for increased burden of disease (much like LDH), and/or indicates the presence of an intrinsically more resistant tumor. Supporting this latter hypothesis is the fact that baseline anemia in the current analysis was associated with several factors that are themselves associated with poorer outcome in SCLC. 
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Significant anemia of at least grade 2 was observed in 55% of patients during their treatment course; this was more likely to occur in females, those >65, and those who were anemic at presentation. There are less data on the impact of anemia arising during therapy for patients treated with chemoradiation for LD-SCLC. In keeping with the hypothesis that anemia increases tumor hypoxia and thus radioresistance, others have found that preradiotherapy anemia [11] or a drop in Hb of >10 g/l [12] , are associated with decreased overall survival in these patients. The current study, however, did not find any negative association between outcomes and the nadir Hb or the maximum percentage drop in Hb during therapy. Instead, a trend towards ÔimprovedÕ local control was observed among patients who had the greatest drop in their Hb during their therapy. The failure of an improvement in local control to translate into an improvement of overall survival is not unexpected in a systemic disease such as SCLC. It is interesting to note that while males were more likely to have anemia at baseline, females were more likely to develop anemia during therapy. In another analysis of trials carried out by the NCIC CTG in both LD-and extensive stage-SCLC [21] , females were more likely to suffer hematological toxicity, including anemia, but despite this, females did not have lower dose intensity than males, and female gender is consistently found to be a favorable prognostic factor in SCLC An association between increased hematological toxicity and improved survival has been observed in other malignancies. For example, an analysis of another NCIC CTG clinical trial (JBR.10) of adjuvant chemotherapy versus observation following complete resection of NSCLC has shown that those patients who have the greatest percentage drop in their Hb while receiving adjuvant chemotherapy have a significantly longer survival [22] . Neutropenia has been shown to be associated with improved outcome in patients receiving adjuvant chemotherapy for breast cancer [23, 24] and in patients receiving chemotherapy for metastatic NSCLC [25] .
If this trend reflects a true association, and not merely a chance finding of multiple statistical comparisons, it indicates that this may be a marker for some facet of increased treatment intensity in those patients who develop the greatest degree of anemia. Although the results of the current analysis did not change when dose intensity of chemotherapy and radiation were incorporated into the statistical model, dose intensity is not necessarily indicative of dose effect for an individual patient. It is recognized that dosing based on BSA has little relationship to individual patient pharmacokinetics or pharmacodynamics. For example, in a study of patients with SCLC undergoing chemotherapy with a regimen of doxorubicin-ifosfamide-etoposide, no correlation with BSA and the clearance of any of the drugs was detected [26] . Others have likewise shown that etoposide clearance is related to several factors, including serum albumin and creatinine, but not to BSA [27] , while only a weak correlation has been detected between cisplatin clearance and BSA [28] . Both cisplatin and etoposide show large interpatient variability which is not explainable by BSA [26, 28] . The most common method of calculating BSA, the DuBois formula [29] , has been reported to overestimate the true BSA by at least 15% in one-sixth of patients [30] , and this may partly explain the increased treatment-emergent anemia in those with a BSA <2.
Anemia may have different prognostic implications at different times in the disease course. At diagnosis, it may be a negative prognostic factor, reflecting disease burden, while if it arises during therapy (particularly in those who were not anemic at baseline), it may be a positive factor. In either situation, correction of the anemia per se is unlikely to have an affect on outcome. In fact, it may be that to improve outcome, hematologic toxicity should be a target of therapy. It is possible, however, that correction of such a resulting anemia would improve quality of life and/or tolerance of therapy, and this requires further study.
Given that the data regarding the impact of anemia on outcomes of therapy in this and other malignancies are conflicting, caution is warranted regarding the routine use of erythropoietin in patients undergoing curative combined modality treatment protocols. A blinded randomized trial adding erythropoietin to standard chemoradiation for LD-SCLC was halted early due to a higher rate of thrombotic events in the experimental arm [31] ; no improvement in outcome was observed despite a clear increase in Hb levels in the erythropoietin arm. Two randomized trials adding erythropoietin to definitive radiotherapy for squamous cell carcinoma of the head and neck have been reported [32, 33] . Neither showed a benefit from the addition of erythropoietin, despite higher mean Hb levels in the active treatment arms; in fact one trial [32] indicates that the addition of erythropoietin may be detrimental to outcome. Thus, despite the consistent finding in head and neck cancer that preradiotherapy anemia is negatively prognostic, correction of such an anemia with the use of erythropoietin has not been shown to improve outcomes of therapy. These findings challenge the assumption that correction of anemia with erythropoietin will improve tumor oxygenation and hence radiosensitivity. A mathematical model of blood flow indicates that maximal oxygen deliver occurs at a Hb value of 110 g/l, and that a significant drop in tumor oxygenation would not occur until <80 g/l [34] . Further, erythropoietin receptors have been detected on a variety of tumor cells, and erythropoietin may have antiapoptotic and/or proliferative activity [35] . A retrospective review of a subset of patients enrolled to one of the randomized trials of erythropoietin or placebo added to radiotherapy for advanced squamous cell carcinoma of the head and neck has been carried out [36] . It revealed that two-thirds of tumors stained positively for erythropoietin receptors, and in those receptor-positive patients, the use of erythropoietin was associated with a poorer locoregional progression-free survival; erythropoietin use was not detrimental in those patients with receptor-negative tumors.
Thus, in the absence of data that use of erythropoietin improves outcome in LD-SCLC or any other malignancy and given the theoretical risk of tumor protection and promotion and the known risk of thrombotic events, transfusions remain an acceptable, and cheaper, option for the treatment of anemia in these patients. Prospective clinical trials are needed to evaluate the relative merits of transfusions versus exogenous erythropoietin, different target original article
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Hb levels, and the differential impact of erythropoietin on receptor-positive and -negative tumors.
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